Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?

Abstract excerpt

Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Blast Crisis
• Share to Hematopoietic Stem Cell Transplantation